Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Rezlidhia FDA Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation

December 2022 Vol 8 No 6

In December 2022, the FDA approved Rezlidhia (olutasidenib; from Forma Therapeutics), a new oral IDH1 inhibitor, for adults with relapsed (coming back) or refractory (not responding to therapy) acute myeloid leukemia (AML) and a susceptible IDH1 mutation, as detected by an FDA-approved test, which was approved on the same day.

This approval was based on an open-label, single-arm, multicenter clinical trial that included 147 patients with relapsed or refractory AML and an IDH1 mutation. Patients received Rezlidhia twice daily until disease progression, unacceptable side effects, or having a transplant. The average duration of treatment with Rezlidhia was 4.7 months, and 16 patients had a transplant after receiving this new medication.

Overall, 32% of the patients had complete remission with Rezlidhia and 2.7% of the patients had complete remission with partial hematologic recovery. The average duration of complete remission or complete remission with hematologic recovery was 25.9 months.

Of the 86 patients who were receiving red blood cell and/or platelet transfusions before the start of the study, 29 patients no longer needed transfusions during any 56 days after starting treatment. Of the 61 patients who did not need transfusions at the beginning of the study, 39 patients remained transfusion-free during any 56 days after starting treatment with Rezlidhia.

The most common side effects reported with Rezlidhia were nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis. Rezlidhia is associated with serious risk for differentiation syndrome, which can be fatal.

Recommended For You